IVERIC bio

104 articles about IVERIC bio

• Iveric Bio Announces Completion of Rolling NDA Submission to FDA for Avacincaptad Pegol for the Treatment of Geographic Atrophy

  12/20/2022

  IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol (ACP), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 02, 2022

  12/2/2022

  IVERIC bio, Inc. reported that on December 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to nine newly-hired, non-executive employees.

• Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock - December 01, 2022

  12/1/2022

  IVERIC bio, Inc., announced the pricing of an upsized underwritten public offering of 13,350,000 shares of its common stock at a price to the public of $22.50 per share, less underwriting discounts and commissions.

• Iveric Bio Announces Proposed Offering of Common Stock - November 30, 2022

  11/30/2022

  IVERIC bio, Inc., announced that it is commencing an underwritten public offering of $250.0 million of shares of its common stock.

• Iveric Bio Announces FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol for Geographic Atrophy

  11/17/2022

  IVERIC bio, Inc. (Nasdaq: ISEE) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura®), a novel investigational complement C5 inhibitor for the treatment of geographic atrophy (GA) secondary to Age-Related Macular Degeneration (AMD).

• Iveric Bio to Present at Upcoming November 2022 Investor Conferences

  11/4/2022

  IVERIC bio, Inc. announced that Iveric Bio management will participate in fireside chats at the following investor conferences in November.

• Iveric Bio Reports Third Quarter 2022 Operational Highlights and Financial Results

  11/3/2022

  IVERIC bio, Inc. announced financial and operating results for the third quarter ended September 30, 2022 and provided a general business update.

• Iveric Bio Announces Submission of First Part of NDA for Rolling Review of Avacincaptad Pegol for the Treatment of Geographic Atrophy

  11/3/2022

  IVERIC bio, Inc. announced that it has submitted to the U.S. Food and Drug Administration the first part of its New Drug Application for rolling review of avacincaptad pegol a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy secondary to Age-Related Macular Degeneration.

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - November 02, 2022

  11/2/2022

  IVERIC bio, Inc. reported that on November 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to eight newly-hired, non-executive employees.

• Iveric Bio to Report Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 3, 2022

  10/27/2022

  IVERIC bio, Inc. (Nasdaq: ISEE) today announced that it will report its third quarter 2022 financial and operating results on Thursday, November 3, 2022.

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 04, 2022

  10/4/2022

  IVERIC bio, Inc. reported that on October 3, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

• Iveric Bio to Present Top-line Results for Avacincaptad Pegol from Phase 3 GATHER2 Clinical Trial in Geographic Atrophy at AAO 2022 Annual Meeting

  9/27/2022

  IVERIC bio, Inc. (Nasdaq: ISEE) announced today that top-line efficacy and safety results from GATHER2, the Company’s second Phase 3 clinical trial of avacincaptad pegol (ACP, also known as Zimura ® ), an investigational complement C5 inhibitor being evaluated for the treatment of geographic atrophy (GA), will be presented at the American Academy of Ophthalmology 2022 annual meeting (AAO 2022) in Chicago, September 30 – October 3.

• Iveric Bio to Present at Upcoming September 2022 Investor Conferences

  9/7/2022

  IVERIC bio, Inc. announced that Glenn P. Sblendorio, Chief Executive Officer, and Pravin U. Dugel, M.D., President, will participate in fireside chats at the following two investor conferences in September.

• Iveric Bio Announces Positive Topline Data from Zimura® GATHER2 Phase 3 Clinical Trial in Geographic Atrophy

  9/6/2022

  IVERIC bio, Inc. announced positive topline results from GATHER2, the Company’s second Phase 3 clinical trial of Zimura®, a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy.

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 02, 2022

  9/2/2022

  IVERIC bio, Inc. reported that on September 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

• Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

  8/10/2022

  Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.

• Iveric Bio to Present at the Wedbush PacGrow Healthcare Conference 2022

  8/3/2022

  IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer, and Keith Westby, Chief Operating Officer, will participate in a fireside chat at the Wedbush PacGrow Healthcare Conference 2022 on Tuesday, August 9, 2022, at 1:45 p.m. Eastern Time.

• Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 02, 2022

  8/2/2022

  IVERIC bio, Inc. reported that on August 1, 2022, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to two newly-hired, non-executive employees.

• Iveric Bio Reports Second Quarter 2022 Operational Highlights and Financial Results

  7/26/2022

  IVERIC bio, Inc. announced financial and operating results for the second quarter ended June 30, 2022 and provided a general business update.

• Iveric Bio Announces Agreement for Up to $250 Million in Non-Dilutive Debt Financing with Hercules Capital and Silicon Valley Bank

  7/26/2022

  IVERIC bio, Inc. announced that it has entered into a term loan debt financing facility with Hercules Capital, Inc. and Silicon Valley Bank providing the Company with total borrowing capacity of up to $250 million in non-dilutive debt financing.